Chief Accounting Officer
Starling Oncology, Inc. (STLN)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Robert Carter is recorded as CFO and Chief Accounting Officer at Starling Oncology, Inc. (STLN). Starling Oncology, Inc. reported in an 8-K filed September 23, 2024 that Robert Carter was appointed Chief Financial Officer, effective October 14, 2024. Starling Oncology, Inc. reported in an 8-K filed September 23, 2024 that Robert Carter was appointed principal accounting officer, effective October 14, 2024. The proxy statement of Starling Oncology, Inc. reports total compensation of $734,130 for Robert Carter in fiscal 2025, including a base salary of $390,000. Disclosed compensation is on record for 2 fiscal years. Robert Carter has spoken on 1 earnings call across 1 company, most recently for Starling Oncology, Inc. on August 13, 2025.
“On September 20, 2024, the Company appointed Robert Carter to replace Mr. Shah as the Company's Chief Financial Officer, with effect on October 14, 2024, and in such role, he will serve as the Company's principal financial officer and principal accounting officer.”
“On September 20, 2024, the Company appointed Robert Carter to replace Mr. Shah as the Company's Chief Financial Officer, with effect on October 14, 2024, and in such role, he will serve as the Company's principal financial officer and principal accounting officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2024-10-14–present
Start not stated–present
Recorded roles and call appearances connecting this person to public companies.
CFO, Chief Accounting Officer
2024-10-14–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Starling Oncology, Inc. (STLN) | — | $390,000 | $734,130 |
| 2024 | Starling Oncology, Inc. (STLN) | — | $288,750 | $434,404 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
